Current issue
Archive
Manuscripts accepted
About the Journal
Editorial office
Editorial board
Abstracting and indexing
Subscription
Contact
Ethical standards and procedures
Most read articles
Instructions for authors
Article Processing Charge (APC)
Regulations of paying article processing charge (APC)
LIPID DISORDERS / RESEARCH LETTER
Lipoprotein(a) and other risk factors in dyslipidemic patients with and without heart failure
1
Department of Preventive Cardiology and Lipidology, Medical University of Lodz (MUL), Lodz, Poland
2
Department of Cardiology and Adult Congenital Heart Diseases, Polish Mother’s Memorial Hospital Research Institute (PMMHRI), Lodz, Poland
3
Faculty of Medicine, John Paul II Catholic University of Lublin, Lublin, Poland
4
Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, MD, USA
Submission date: 2024-09-22
Final revision date: 2024-10-13
Acceptance date: 2024-10-14
Online publication date: 2024-10-16
Corresponding author
Maciej Banach
Department of Preventive Cardiology and Lipidology, Medical University of Lodz (MUL), Lodz, Poland, Lodz, Poland
Department of Preventive Cardiology and Lipidology, Medical University of Lodz (MUL), Lodz, Poland, Lodz, Poland
TOPICS
REFERENCES (15)
1.
Banach M, Burchardt P, Chlebus K, et al. PoLA/CFPiP/PCS/ PSLD/PSD/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021. Arch Med Sci 2021; 17: 1447-547.
2.
McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021; 42: 3599-726.
3.
Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, et al. Lipoprotein(a) reduction in persons with cardiovascular disease. N Engl J Med 2020; 382: 244-55.
4.
Sosnowska B, Stepinska J, Mitkowski P, et al. Recommendations of the Experts of the Polish Cardiac Society (PCS) and the Polish Lipid Association (PoLA) on the diagnosis and management of elevated lipoprotein(a) levels. Arch Med Sci 2024; 20: 8-27.
5.
Wu B, Zhang Z, Long J, Zhao H, Zeng F. Association between lipoprotein (a) and heart failure with reduced ejection fraction development. J Clin Lab Anal 2022; 36: e24083.
6.
Singh S, Baars DP, Aggarwal K, Desai R, Singh D, Pinto-Sietsma SJ. Association between lipoprotein (a) and risk of heart failure: a systematic review and meta-analysis of mendelian randomization studies. Curr Probl Cardiol 2024; 49: 102439.
7.
Sosnowska B, Lewek J, Adach W, et al. The prevalence, patients’ characteristics, and hyper-Lp(a)-emia risk factors in the Polish population. The first results from the PMMHRI-Lp(a) Registry. Prog Cardiovasc Dis 2024; S0033-0620(24)00115-4.
8.
Banach M, Reiner Z, Cicero AFG, et al. 2022: the year in cardiovascular disease – the year of upfront lipid lowering combination therapy. Arch Med Sci 2022; 18: 1429-34.
9.
Velavan P, Huan Loh P, Clark A, Cleland JGF. The cholesterol paradox in heart failure. Congest Heart Fail 2007; 13: 336-41.
10.
Hovland A, Mundal LJ, Igland J, et al. Increased risk of heart failure and atrial fibrillation in heterozygous familial hypercholesterolemia. Atherosclerosis 2017; 266: 69-73.
11.
Charach G, Argov O, Nochomovitz H, Rogowski O, Charach L, Grosskopf I. A longitudinal 20 years of follow up showed a decrease in the survival of heart failure patients who maintained low LDL cholesterol levels. QJM Int J Med 2018; 111: 319-25.
12.
Horwich TB, Hernandez AF, Dai D, Yancy CW, Fonarow GC. Cholesterol levels and in-hospital mortality in patients with acute decompensated heart failure. Am Heart J 2008; 156: 1170-6.
13.
Yan J, Pan Y, Xiao J, et al. High level of lipoprotein(a) as predictor for recurrent heart failure in patients with chronic heart failure: a cohort study. Arq Bras Cardiol 2019; 113: 197-204.
14.
Li Z, Liu J, Shen J, et al. Association of lipoprotein (a) and 1 year prognosis in patients with heart failure with reduced ejection fraction. ESC Heart Fail 2022; 9: 2399-406.
15.
Gudbjartsson DF, Thorgeirsson G, Sulem P, et al. Lipoprotein(a) concentration and risks of cardiovascular disease and diabetes. J Am Coll Cardiol 2019; 74: 2982-94.
| eISSN: | 1896-9151 |
| ISSN: | 1734-1922 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
